July 19, 2019

Drugs vs. Bugs — the Bugs are Winning

SciBac, for one, last month decided to pivot its “bugs-as-drugs” technology, which uses bacteria as a way to deliver antibiotics, toward drug-resistant bacteria in chronic cystic fibrosis infections. The inhaled antibiotic potentially offers less competition, Mucha said, as well as application once or twice a month that could attack active and inactive bacteria hibernating in the biofilm of the lungs.


July 9, 2019

SciBac Awarded NIH Grant for Novel Treatment of Lung Infections Associated with Cystic Fibrosis

SciBac a developer of innovative live biotherapeutics, announced today the award of a $286,530 grant from the National Institutes of Health (NIH). The grant will fund work to advance the development of a novel live biotherapeutic, SCB-211, for the treatment of nontuberculous mycobacteria (NTM) lung infection associated with cystic fibrosis.


October 9, 2018

Why Peter Thiel is backing a tiny start-up waging war against the global superbug crisis

SciBac, a biotherapeutics company named to the 2018 CNBC Upstart 100 list. The Silicon Valley start-up shifts the paradigm on how to tackle superbugs. It is developing a microbe pill to boost the body's microbiome in the gut, lungs and skin to kill bacteria that cause antibiotic-resistant disease.

October 9, 2018

CNBC unveils its annual list of 100 promising start-ups to watch

SciBac is on CNBC's Upstart 100 list -- promising global startups to watch in 2018, that are "breaking industry barriers on the path to becoming tomorrow's household names."

September 20, 2018

Fighting fire with fire – boosting the microbiome

CARB-X’s annual report highlights SciBac’s important contribution to the fight against antibiotic resistance.

September 12, 2018

SciBac – CLSI FAST Graduate Wins Up To $3.76M From CARB-X

July 31, 2018

SciBac Awarded up to $3.76M by CARB-X to Develop Hybrid Microbes as a Drug for C. diff

SciBac has been awarded up to $3.76 million in non-dilutive funding by CARB-X, a public-private partnership devoted to accelerating early medical R&D to combat the rising threat of antibiotic resistant Superbugs. This award supports development of SciBac’s novel biotherapeutic to treat and prevent Clostridium difficile infections (CDI). 


January 28, 2018

Startup Fire Interview with SciBac CEO Jeanette Mucha

Learn all about CEO Jeanette Mucha, the story of how SciBac was founded, MERGE technology, and the biotherapeutic pipeline that harnesses the microbiome to tackle antibiotic resistant diseases.

January 27, 2018

SciBac to present at The Human Microbiome: Time for Effective Translation

SciBac to present at 11:15 am, March 30 2018 at UCLA California Nanosystems Institute, Los Angeles, CA.


January 1, 2018

SciBac to present at Biotech Showcase on Jan 10

SciBac CEO, Jeanette Mucha, to present at the Biotech Showcase™ Annual Conference on January 10, 2018, 1:45pm at Hilton Union Square, Room Franciscan -  A.


September 19, 2017

SciBac Issued Patent for its Platform MERGE Technology

U.S. patent just issued for SciBac's "Method for Producing Chimeric Microbial Hybrids."


July 18, 2017

SciBac Announces Strain Development Project with Novozymes

SciBac will use its MERGE technology platform to develop non-GMO hybrid microorganisms for the purpose of creating a cost-efficient expression of enzymes for Novozymes.


May 3, 2017

BIO Announces 2017 Start-Up Stadium Finalists

Empowering the Cutting-Edge Companies of Tomorrow, Today SciBac announced as a finalist, having been judged by experts with entrepreneurial, investment, start-up, economic development, capital formation, and academic backgrounds from both the public and private sectors.

Apr 13, 2017

Thiel’s Breakout Labs fuels four new life science companies

Jeanette Mucha, CEO of SciBac, said: “The Breakout Labs grant will allow us to further advance our C. diff program, developing a live biotherapeutic that can destroy the harmful C. diff pathogen without antibiotics, while nurturing a healthy gut microbiome.”